Menges T, Welters I, Wagner R M, Boldt J, Dapper F, Hempelmann G
Department of Anaesthesiology and Intensive Care Medicine, Justus-Liebig-University, Giessen, Germany.
Eur J Cardiothorac Surg. 1997 Mar;11(3):557-63. doi: 10.1016/s1010-7940(96)01093-7.
Withdrawal of autologous plasma and reinfusion after cardiopulmonary bypass (CPB) offers the opportunity of improving patients' haemostasis and reducing homologous blood consumption in cardiac surgery. The influence of acute, preoperative plasmapheresis (APP) on coagulation tests, fibrinolysis, blood loss and transfusion requirements was investigated in elective aortocoronary bypass patients.
Forty patients were randomized to a control or pheresis group. The pheresis group had platelet-rich plasmapheresis (PRP-group, n = 20) performed before incision and the platelet-rich plasma (PRP) was returned after CPB. The control group (n = 20) was managed without pheresis. All patients had serial coagulation studies, including prothrombin split products (F1/F2), fibrinopeptide A (FPA), protein C (PC), thrombomodulin (TM), tissue-plasminogen-activator (t-PA), plasminogen-activator-inhibitor (PAI 1), fibrinopeptide B beta 15-42 (FPB beta 15-42), haemoglobin and platelet counts determined intra- and postoperatively. Chest tube drainage and transfusion requirements were recorded.
APP had no negative effects on the quality of PRP. The platelet count of the withdrawn autologous plasma was 239 +/- 33 x 10(9)/l. From the end of the operation (after retransfusion of autologous plasma) until the first postoperative day platelet counts were significant higher in the PRP-group (P > 0.05). Plasma concentrations of modified antithrombin III (ATM), F1/F2 and FPA increased (166-290% from baseline) and PC- and TM-antigen decreased (11-49% from baseline) to a different extent for both groups throughout CPB. t-PA-activity increased intraoperatively peaking at the end of CPB (PRP-group: 4.8 +/- 0.8 IU/ml, control-group: 8.1 +/- 2.3 IU/ml)(P > 0.05). With onset of CPB PAI-1 levels decreased and were further reduced after CPB in control patients in comparison to PRP-patients (P < 0.05). FPB beta 15-42 occurred in peak concentrations after neutralisation of heparin by protamine. Only PRP-patients showed baseline values of coagulation and fibrinolytic parameters on the next morning (P < 0.05). Total postoperative blood loss during the first 24 h was 503 +/- 251 ml (PRP-group) and 937 +/- 349 ml in the control-group (P < 0.05). None of the PRP-patients received allogeneic blood, whereas five control-patients received 11 units of packed red cells (P < 0.05).
The findings suggest that in elective cardiac surgery heparin cannot prevent generation of both thrombin and fibrin, born throughout CPB and postoperatively. The use of PRP withdrawn immediately preoperatively is an attractive technique to reduce allogeneic blood usage and preoperative blood loss, especially in patients in whom withdrawal of autologous whole blood cannot be performed.
体外循环(CPB)后抽取并回输自体血浆为改善心脏手术患者的止血功能及减少异体血使用提供了机会。本研究在择期主动脉冠状动脉搭桥手术患者中,探讨了急性术前血浆置换(APP)对凝血试验、纤维蛋白溶解、失血及输血需求的影响。
40例患者随机分为对照组和血浆置换组。血浆置换组在切开前进行富含血小板血浆置换(PRP组,n = 20),并在CPB后回输富含血小板血浆(PRP)。对照组(n = 20)未进行血浆置换。所有患者均进行了系列凝血研究,包括凝血酶原裂解产物(F1/F2)、纤维蛋白肽A(FPA)、蛋白C(PC)、血栓调节蛋白(TM)、组织型纤溶酶原激活剂(t-PA)、纤溶酶原激活剂抑制剂(PAI 1)、纤维蛋白肽Bβ15 - 42(FPBβ15 - 42),并在术中和术后测定血红蛋白及血小板计数。记录胸管引流量及输血需求。
APP对PRP质量无负面影响。所抽取自体血浆的血小板计数为239±33×10⁹/L。从手术结束(自体血浆回输后)至术后第1天,PRP组的血小板计数显著更高(P > 0.05)。在整个CPB过程中,两组改良抗凝血酶III(ATM)、F1/F2和FPA的血浆浓度均有不同程度升高(较基线升高166 - 290%),而PC和TM抗原降低(较基线降低11 - 49%)。t-PA活性在术中升高,并在CPB结束时达到峰值(PRP组:4.8±0.8 IU/ml,对照组:8.1±2.3 IU/ml)(P > 0.05)。CPB开始时,PAI-1水平下降,与PRP组患者相比,对照组患者在CPB后进一步降低(P < 0.05)。在鱼精蛋白中和肝素后,FPBβ15 - 42出现峰值浓度。仅PRP组患者在术后次日显示凝血和纤溶参数的基线值(P < 0.05)。术后第1个24小时的总失血量,PRP组为503±251 ml,对照组为937±349 ml(P < 0.05)。PRP组患者均未输注异体血,而5例对照组患者输注了11单位浓缩红细胞(P < 0.05)。
研究结果表明,在择期心脏手术中,肝素无法预防CPB期间及术后产生的凝血酶和纤维蛋白。术前即刻抽取PRP的方法是一种有吸引力的技术,可减少异体血使用及术前失血,尤其适用于无法抽取自体全血的患者。